GW Pharmaceuticals, the English drug maker planning a U.S. initial public offering, is working with outside communications counsel and hired a U.S.-based PR and investor relations exec.
GW, based in Wilshire, U.K., said this week that Stephen Schultz joined the company as VP of IR in the U.S. Schultz most recently was Connecticut-based senior director of IR and corporate comms. at Irish drug maker Amarin and earlier held posts with the Jackson Hole Center for the Arts (executive director), Acusphere (dir., corporate comms.) and Shareholder.com (dir., IR, corporate governance), among others.
GW is working with FTI Consulting for strategic communications counsel and New York-based Trout Group for IR support.
The company said March 19 that the number of shares to be offered and price range have not yet been determined, although its filing shows it hopes to raise up to $50M.
In a statement, GW CEO Justin Gover said hiring Schultz is “intended to provide us with an important new resource as we prepare for a future which is increasingly focused on the U.S. market.”
GW’s Sativex is approved for multiple sclerosis in 20 countries and is in Phase 3 trials for treating cancer pain. It plans to list its American Depository Shares on the Nasdaq.
Revenue for fiscal 2012 was $53M.
Have a comment? Send it to 
No comments have been submitted for this story yet.